Latest News about RHHBY
Recent news which mentions RHHBY
From Benzinga
From Motley Fool
3 COVID Stocks That Can Turn $1,000 Into $10,000
October 12, 2021
From Motley Fool
From Benzinga
From Motley Fool
Roche's Alzheimer's Candidate Secures FDA Breakthrough Designation
October 08, 2021
From Benzinga
From Motley Fool
Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst
October 06, 2021
From Benzinga
Why Novavax Stock Plunged in September
October 06, 2021
From Motley Fool
Moderna Is Down 12%. Is It Time to Buy?
October 06, 2021
From Motley Fool
Which COVID-19 Pill Stock Is the Best Buy?
October 05, 2021
From Motley Fool
2 Best Biotech Stocks to Buy In October
October 04, 2021
From Motley Fool
3 Stocks That Might Soar With Pills for COVID
October 03, 2021
From Motley Fool
Here Are the Leaders in the Race to Develop a COVID-19 Pill
October 03, 2021
From Motley Fool
From Benzinga
Labcorp's At Home Collection Kit Gets EUA Nod For Combined COVID-19 and Flu Detection
October 01, 2021
From Benzinga
From Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
From Benzinga
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
September 30, 2021
From Benzinga
3 COVID Stocks Ready to Take On the Delta Variant
September 27, 2021
From Motley Fool
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
September 27, 2021
From Benzinga
3 Biotech Stocks That Could Make You Filthy Rich
September 27, 2021
From Motley Fool
Acceleron In Advanced $11B Buyout Talks: Bloomberg
September 27, 2021
From Benzinga
September Sell-Off Alert: Buy Vertex Pharmaceuticals on the Dip
September 25, 2021
From Motley Fool
Roche Builds Case For Evrysdi Benefits In Younger Spinal Muscular Atrophy Patients
September 24, 2021
From Benzinga
WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access
September 24, 2021
From Benzinga
Here's Why Everyone's Talking About AstraZeneca Right Now
September 21, 2021
From Motley Fool
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
September 20, 2021
From Benzinga
With Prothena Up Over 500% This Year, Is It Too Late to Get in?
September 18, 2021
From Motley Fool
Why Adaptimmune Therapeutics Was Sinking This Week
September 17, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.